Antisperm Antibody in Testicular Cancer Patients

测定了47例生殖细胞癌患者血清中抗精子抗体水平；17例为睾丸精原细胞瘤，26例为非精原细胞瘤性睾丸生殖细胞瘤，4例为睾丸外非精原细胞瘤性生殖细胞瘤。使用间接精子固定试验（Isojima法）和间接酶联免疫吸附试验（ELISA）评估抗精子抗体的存在。精子固定化试验无患者血清抗精子抗体阳性，ELISA检测血清抗精子抗体效价大于1:32者有12例（25.5%）阳性。35.5%的睾丸精原细胞瘤患者抗体阳性，15.4%的非精原细胞瘤患者抗体阳性，50%的睾丸外生殖细胞瘤患者抗体阳性。ELISA检测抗精子抗体阳性的发生率与肿瘤组织学及疾病分期无相关性。患者血清中抗体的含量与治疗成功后患者血清中抗体的含量无统计学差异。有几例患者在治疗后3年以上抗体呈阳性。目的探讨抗精子抗体对睾丸功能的影响。抗体阳性患者精液质量不受影响。抗体阳性患者血清FSH水平升高的发生率不高于抗体阴性患者。总之，使用ELISA评估的睾丸癌患者的抗精子抗体与肿瘤组织学、疾病分期、疾病治疗或生育状况无关。抗精子抗体不能作为睾丸癌的肿瘤标志物。

The level of antisperm antibodies was evaluated in the serum of 47 patients with germ cell cancer ; 17 patients with testicular seminomas, 26 with non-seminomatous testicular germ cell tumors and 4 with extragonadal non-seminomatous germ cell tumors. The presence of antisperm antibodies was assessed using the indirect sperm immobilization test (Isojima's mothod) and the indirect Enzyme-Linked ImmunoSorbent Assay (ELISA). No patients showed a positive antisperm antibody by the sperm immobilization test, while 12 patients (25.5%) showed a positive serum titer of antisperm antibodies more than 1 : 32 by ELISA. The antibody was positive in 35.5% of the patients with testicular seminomas, 15.4% of those with non-seminomatous testicular tumors, and 50% of those with extragonadal germ cell tumors. There was no relation between the incidence of positive antisperm antibodies by ELISA and the tumor histology or the stage of the disease. The incidence of the antibody was not statistically different between the serum from the patients with the disease and those from the patients after the successful treatment. Several patients showed positive antibodies more than 3 years after treatment.Semen quality and serum FSH levels were studied to investigate the effect of the antisperm antibody on the testicular function. Semen quality was not deterirated in the antibody positive patients. Incidence of the elevated serum FSH levels in the antibody positive patients was not higher than that in the antibody negative patients.In conclusion, antisperm antibodies in the testicular cancer patients assessed using ELISA were not related to either tumor histology, stage of the disease, treatment of the disease, or the condition of the fertility. Antisperm antibodies were not useful as a tumor marker of testicular cancer.